Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Equity Average (2016 - 2025)

IGC Pharma (IGC) has disclosed Equity Average for 15 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 7.12% to $7.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.1 million, a 7.12% decrease, with the full-year FY2025 number at $6.8 million, down 38.6% from a year prior.
  • Equity Average was $7.1 million for Q3 2025 at IGC Pharma, up from $6.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $32.3 million in Q2 2021 to a low of $6.2 million in Q2 2025.
  • A 5-year average of $16.7 million and a median of $14.1 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 34.75% in 2021, then tumbled 50.72% in 2024.
  • IGC Pharma's Equity Average stood at $30.4 million in 2021, then tumbled by 36.67% to $19.2 million in 2022, then plummeted by 39.81% to $11.6 million in 2023, then tumbled by 41.1% to $6.8 million in 2024, then grew by 3.92% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Equity Average are $7.1 million (Q3 2025), $6.2 million (Q2 2025), and $6.3 million (Q1 2025).